目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED
1.2.4 CURRENCY CONSIDERED
1.3 MARKET STAKEHOLDERS
1.4 LIMITATIONS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 FLUID MANAGEMENT SYSTEMS MARKET OVERVIEW
4.2 ASIA PACIFIC: FLUID MANAGEMENT SYSTEMS MARKET, BY PRODUCT & COUNTRY (2024)
4.3 FLUID MANAGEMENT SYSTEMS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 FLUID MANAGEMENT SYSTEMS MARKET, REGIONAL MIX, 2023-2030
4.5 FLUID MANAGEMENT SYSTEMS MARKET: EMERGING VS. DEVELOPED ECONOMIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising number of minimally invasive surgeries
5.2.1.2 Increasing prevalence of ESRD
5.2.1.3 Technological advancements in fluid management systems
5.2.1.4 Government funds & grants for endosurgical procedures
5.2.1.5 Rising establishment of endoscopy & laparoscopy facilities in hospitals
5.2.2 RESTRAINTS
5.2.2.1 High cost of endosurgical procedures
5.2.2.2 Lack of consumer & patient awareness
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.3.2 Single-use disposable devices & accessories
5.2.4 CHALLENGES
5.2.4.1 Shortage of surgeons
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2024 (USD)
5.4.2 AVERAGE SELLING PRICE TREND OF INTEGRATED FLUID MANAGEMENT SYSTEMS, BY REGION, 2022-2024 (USD)
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Irrigation/Distension pumps & disposable cassettes
5.9.1.2 Closed fluid waste capture & automated transfer
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 OR/Endoscopy integration, traceability, and connectivity
5.9.2.2 Procedure-specific sterile kits & modular disposables
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Hemodynamic monitoring & decision support
5.9.3.2 Renal support & critical-care circuits (CRRT/Dialysis/ECMO)
5.10 INDUSTRY TRENDS
5.10.1 GRADUAL SHIFT TO CLOSED-LOOP & HANDS-FREE WASTE SYSTEMS
5.10.2 DIGITIZATION, TRACEABILITY, AND CONNECTIVITY
5.11 PATENT ANALYSIS
5.12 TRADE ANALYSIS
5.12.1 IMPORT DATA (HS CODE 901890)
5.12.2 EXPORT DATA (HS CODE 901890)
5.13 KEY CONFERENCES & EVENTS, 2025-2026
5.14 CASE STUDY ANALYSIS
5.14.1 CASE STUDY 1: CLOSED FLUID WASTE MANAGEMENT SYSTEM (STRYKER'S NEPTUNE)-SAFER & FASTER OPERATING ROOM TURNOVERS
5.14.2 CASE STUDY 2: FLUID WARMING SYSTEMS-REDUCING PERIOPERATIVE HYPOTHERMIA
5.14.3 CASE STUDY 3: HEIDELBERG ENGINEERING-NHS UK OCT DEPLOYMENT
5.15 REGULATORY ANALYSIS
5.15.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15.2 REGULATORY FRAMEWORK
5.15.2.1 North America
5.15.2.1.1 US
5.15.2.1.2 Canada
5.15.2.2 Europe
5.15.2.2.1 Germany
5.15.2.2.2 France
5.15.2.2.3 UK
5.15.2.3 Asia Pacific
5.15.2.3.1 India
5.15.2.3.2 China
5.15.2.3.3 Japan
5.15.2.4 Latin America
5.15.2.4.1 Brazil
5.15.2.4.2 Mexico
5.15.2.5 Middle East & Africa
5.15.2.5.1 Middle East
5.15.2.5.2 Africa
5.16 PORTER'S FIVE FORCES ANALYSIS
5.16.1 BARGAINING POWER OF SUPPLIERS
5.16.2 BARGAINING POWER OF BUYERS
5.16.3 THREAT OF NEW ENTRANTS
5.16.4 THREAT OF SUBSTITUTES
5.16.5 INTENSITY OF COMPETITIVE RIVALRY
5.17 KEY STAKEHOLDERS & BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 IMPACT OF AI/GENERATIVE AI ON FLUID MANAGEMENT SYSTEMS MARKET
5.18.1 AI-USE CASES
5.18.2 KEY COMPANIES IMPLEMENTING AI
5.18.3 FUTURE OF AI/GEN AI
5.19 ADJACENT MARKET ANALYSIS
5.20 TRUMP TARIFF IMPACT ON FLUID MANAGEMENT SYSTEMS MARKET
5.20.1 KEY TARIFF RATES
5.20.2 PRICE IMPACT ANALYSIS
5.20.3 KEY IMPACT ON COUNTRY/REGION
5.20.3.1 US
5.20.3.2 Europe
5.20.3.3 Asia Pacific
5.20.4 IMPACT ON END-USER INDUSTRIES

6 FLUID MANAGEMENT SYSTEMS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 SYSTEMS
6.2.1 STANDALONE SYSTEMS
6.2.1.1 Dialyzers
6.2.1.1.1 Rising CKD and ESRD cases globally to fuel consistent demand for dialyzers in fluid management systems
6.2.1.2 Insufflators
6.2.1.2.1 Growing adoption of minimally invasive surgeries to drive demand for insufflators
6.2.1.3 Suction/Evacuation & irrigation systems
6.2.1.3.1 Critical role of these systems in ensuring surgical precision to boost demand
6.2.1.4 Fluid waste management systems
6.2.1.4.1 Reduced risk of cross-contamination and exposure to biohazardous waste to drive adoption
6.2.1.5 Other standalone systems
6.2.2 INTEGRATED SYSTEMS
6.2.2.1 Growing need for accurate and efficient fluid management to support market growth
6.3 DISPOSABLES & ACCESSORIES
6.3.1 CATHETERS
6.3.1.1 Recurring demand for single-use catheters to support sustained revenue growth in market
6.3.2 BLOODLINES
6.3.2.1 Advancements in bloodline design and safety to fuel segment growth
6.3.3 TUBING SETS
6.3.3.1 Increasing patient safety awareness to accelerate demand for sterile tubing sets in hospitals and clinics
6.3.4 PRESSURE MONITORING LINES
6.3.4.1 Technological advancements in monitoring devices to enhance utility of pressure monitoring lines in critical care
6.3.5 PRESSURE TRANSDUCERS
6.3.5.1 Increasing patient safety awareness to accelerate demand in hospitals and clinics
6.3.6 VALVES, CONNECTORS, AND FITTINGS
6.3.6.1 Increased focus on infection prevention to boost market
6.3.7 SUCTION CANISTERS
6.3.7.1 Disposable suction canisters to gain traction due to stricter infection control and contamination prevention protocols
6.3.8 CANNULAS
6.3.8.1 Expanding chronic disease treatments to boost cannula utilization in fluid management applications
6.3.9 OTHER DISPOSABLES & ACCESSORIES

7 FLUID MANAGEMENT SYSTEMS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 UROLOGY & NEPHROLOGY
7.2.1 INCREASING PREVALENCE OF CKD AND ESRD TO DRIVE MARKET GROWTH
7.3 GASTROENTEROLOGY
7.3.1 EXPANDING ENDOSCOPY CENTERS IN BOTH DEVELOPED AND EMERGING ECONOMIES TO SUPPORT GROWTH
7.4 GENERAL SURGERY
7.4.1 TECHNOLOGICAL INNOVATIONS IN SURGICAL EQUIPMENT TO FUEL ADOPTION
7.5 ORTHOPEDICS
7.5.1 GROWING NUMBER OF SPECIALIZED ORTHOPEDIC CENTERS TO FUEL GROWTH
7.6 GYNECOLOGY
7.6.1 STRONG DEMAND FOR RELIABLE FLUID REGULATION TECHNOLOGIES TO SUPPORT MARKET GROWTH
7.7 CARDIOVASCULAR SURGERY
7.7.1 ABILITY OF FLUID MANAGEMENT SYSTEMS TO ENSURE STABLE HEMODYNAMICS AND MINIMIZE BLOOD LOSS TO DRIVE GROWTH
7.8 NEUROSURGERY
7.8.1 ADVANCEMENTS IN NEURO-ENDOSCOPY AND IMAGE-GUIDED SURGERIES TO PROPEL MARKET GROWTH
7.9 ENT
7.9.1 INCREASING PREVALENCE OF ENT DISORDERS TO SUPPORT GROWTH
7.10 OTHER APPLICATIONS

8 FLUID MANAGEMENT SYSTEMS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 ADVANCED INFRASTRUCTURE, SPECIALIZED OPERATING ROOMS, AND HIGHLY SKILLED MEDICAL PROFESSIONALS TO BOOST MARKET
8.3 DIALYSIS CENTERS
8.3.1 INCREASING NUMBER OF PATIENTS REQUIRING LONG-TERM DIALYSIS CARE TO EXPAND MARKET
8.4 AMBULATORY SURGICAL CENTERS
8.4.1 RISING PREFERENCE FOR OUTPATIENT SURGERIES TO BOOST GROWTH
8.5 OTHER END USERS

9 FLUID MANAGEMENT SYSTEMS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 Growing ASC migration and OSHA compliance to accelerate adoption of fluid management systems
9.2.3 CANADA
9.2.3.1 Growing biosafety requirements to boost adoption of standardized, closed-loop fluid handling consumables nationwide
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Multi-year public tenders and regional procurement structures to drive uniform adoption of closed-loop fluid handling systems
9.3.3 FRANCE
9.3.3.1 High procedure throughput, rapid ambulatory adoption, and codified biosafety rules to support market growth
9.3.4 UK
9.3.4.1 High NHS funding and sustained diagnostic capacity build-out to boost growth
9.3.5 ITALY
9.3.5.1 Large hospital network and steadily aging population to contribute to market growth
9.3.6 SPAIN
9.3.6.1 High hospital throughput and codified exposure-control expectations to propel market
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 JAPAN
9.4.2.1 Aging demographics and high exam/surgery capacity to boost market
9.4.3 CHINA
9.4.3.1 Large care volumes, dense hospital infrastructure, and broad insurance coverage to support growth
9.4.4 INDIA
9.4.4.1 High prevalence of diabetes and increasing awareness about eye health to fuel market
9.4.5 SOUTH KOREA
9.4.5.1 Universal coverage and high endoscopy throughput to drive market growth
9.4.6 AUSTRALIA
9.4.6.1 High caseloads and mixed public-private hospital base to propel growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Large inpatient volumes and critical care capacity to aid growth
9.5.3 MEXICO
9.5.3.1 Expanding insured base in Mexico to boost adoption
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 ESTABLISHED SAFETY STANDARDS TO DRIVE ADOPTION OF FLUID MANAGEMENT SYSTEMS
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.7 GCC COUNTRIES
9.7.1 GROWING NUMBER OF FORMAL PROCUREMENT PROGRAMS ACROSS PUBLIC AND PRIVATE HEALTHCARE PROVIDERS TO FUEL GROWTH
9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN FLUID MANAGEMENT SYSTEMS MARKET
10.3 REVENUE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product footprint
10.5.5.4 Application footprint
10.5.5.5 End-user footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of startups/SMEs
10.7 COMPANY VALUATION AND FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT ENHANCEMENTS
10.9.2 DEALS

11 COMPANY PROFILE
11.1 KEY PLAYERS
11.1.1 FRESENIUS MEDICAL CARE AG
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product enhancements
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 CARDINAL HEALTH
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Other developments
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 BAXTER INTERNATIONAL INC.
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 MnM view
11.1.3.3.1 Key strengths
11.1.3.3.2 Strategic choices
11.1.3.3.3 Weaknesses & competitive threats
11.1.4 OLYMPUS CORPORATION
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 MnM view
11.1.4.3.1 Key strengths
11.1.4.3.2 Strategic choices
11.1.4.3.3 Weaknesses & competitive threats
11.1.5 B. BRAUN SE
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Other developments
11.1.5.4 MnM view
11.1.5.4.1 Key strengths
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 STRYKER
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.7 MEDTRONIC
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Other developments
11.1.8 JOHNSON & JOHNSON
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.9 SMITH & NEPHEW PLC
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 NIPRO CORPORATION
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.11 CONMED CORPORATION
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.12 ECOLAB INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.13 HOLOGIC, INC.
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.14 ZIMMER BIOMET HOLDINGS, INC.
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.15 ICU MEDICAL, INC.
11.1.15.1 Business overview
11.1.15.2 Products offered
11.2 OTHER PLAYERS
11.2.1 KARL STORZ GMBH & CO. KG
11.2.2 ACTEON MEDICAL
11.2.3 MEDLINE INDUSTRIES, LP
11.2.4 DEROYAL INDUSTRIES, INC.
11.2.5 MOLNLYCKE HEALTH CARE AB
11.2.6 TIANJIN ZHICHAO MEDICAL TECHNOLOGY CO., LTD.
11.2.7 HUNAN HONYMED CO., LTD.
11.2.8 SCIVITA MEDICAL
11.2.9 HANGZHOU VALUED MEDTECH CO., LTD.
11.2.10 SERENNO MEDICAL

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS